Open AccessEffect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
Author(s) -
Mizue Ichinose,
Itaru Miura,
Sho Horikoshi,
Shinnosuke Yamamoto,
Keiko KannoNozaki,
Kenya Watanabe,
Hirooki Yabe
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s306573
Subject(s) - schizoaffective disorder , homovanillic acid , extrapyramidal symptoms , medicine , schizophrenia (object oriented programming) , antipsychotic , positive and negative syndrome scale , partial agonist , haloperidol , dopaminergic , dopamine , psychosis , endocrinology , pharmacology , psychiatry , agonist , receptor , serotonin
Although switching antipsychotics is a common strategy in the treatment of schizophrenia, caution is needed because of the risk of worsening of psychosis, particularly when switching to a dopamine D2 partial agonist. Homovanillic acid (HVA), a dopamine metabolite, is thought to be a possible indicator of the response to antipsychotics. We examined the effects of switching to brexpiprazole monotherapy from other antipsychotics on plasma HVA levels and side effects during maintenance treatment of schizophrenia.